Security quote of the week [LWN.net]

Security quote of the week

Posted Sep 16, 2021 19:59 UTC (Thu) by Cyberax (✭ supporter ✭, #52523)
In reply to: Security quote of the week by pizza
Parent article: Security quote of the week

> Large Pharma companies routinely spend 2-3x on marketing/advertising as they do on R&D

Everybody is spending comparable amounts on marketing and sales, so this is not an argument at all. Your cereal manufacturer is likely spending more.

Want to lower that number down? Then you need to extend patent protection time. Right now a typical drug remains under patent protection for about 8 years after it's approved (patents are filed before the Phase 1 trials!). So companies have to aggressively promote drugs to have enough time to get profit.

Let's take an example from your list
> GlaxoSmithKline €21,891 €4,568 €11,402

GSK is spending 20% of its revenue on R&D. For comparison, Intel: $13.56B out of $77.9B (17%).

Profit margin for pharma companies is a more complicated story: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054843/

to post comments

Security quote of the week

Posted Sep 16, 2021 20:38 UTC (Thu) by pizza (subscriber, #46) [Link]

> GSK is spending 20% of its revenue on R&D. For comparison, Intel: $13.56B out of $77.9B (17%).

...20% of revenue on R&D, and *over 50%* of revenue on marketing.

Meanwhile, Intel actually spent $19.7 billion, aka 25% of gross revenue, on R&D. They made about $20.9 billion in net profit, leaving $37.3 billion in non-R&D expenses. Of that, $24 billion was attributable to opearating costs (ie salaries and production costs of goods sold), leaving about $13.3B (18%) for everything else, notably including CapEx for future fab expansion.

(My source for this is Intel's 2020 financial report: https://www.intc.com/news-events/press-releases/detail/14... )

> Profit margin for pharma companies is a more complicated story: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054843/

I'm not sure what your point here is, but okay, let's take the summary of findings of that article:

"In this cross-sectional study that compared the profits of 35 large pharmaceutical companies with those of 357 large, nonpharmaceutical companies from 2000 to 2018, the median net income (earnings) expressed as a fraction of revenue was significantly greater for pharmaceutical companies compared with nonpharmaceutical companies (13.8% vs 7.7%)."

...So large pharma companies have a median profit margin 80% higher than non-pharma companies. That doesn't exactly support the assertion that R&D expenses are bleeding big pharma dry.